전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Genentech
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 3Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

7.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Active
CGTLimited DatastaleFondazione Matilde Tettamanti M…Phase 2

CARCIK-CD19 (CARCIK-CD19)

Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART22-65s cells (CART22-65s cells)

Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleInnovative Cellular Therapeutic…Preclinical

CD19CART (CD19CART)

Leukemia, B-Cell; Lymphoma, B-Cell · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 3Status Active
CGTLimited DatastaleBeijing BiotechPhase 1

CD20/BCMA-directed CAR-T cells (CD20/BCMA-directed CAR-T cells)

Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM) · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22CART infusion (CD22CART infusion)

Leukemia; Acute Lymphoblastic Leukemia · CD22

#CD22#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
AntibodyLimited DatastaleUCB PharmaApproved

CZP (Certolizumab Pegol, Certolizumab Pegol (CZP))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#monoclonal-antibody#UCB
Trials 3Status Active
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin+Anlotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 3Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (EB-DT-CAR-NK)

Advanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma · Advanced Gastric Adenocarcinoma

#AdvancedGastricAdenocarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTStandard DatabasestaleImmunityBio, Inc.Phase 2

PSA-based Oncolytic Virus (ETBX-071, ETBX-071 (PSA-based Oncolytic Virus))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 3Status Discontinued
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel CAR-T Therapy (Eque-cel CAR-T Therapy)

AL Amyloidosis · AL Amyloidosis

#ALAmyloidosis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 3Status Recruiting

29 / 103 pages

← PreviousNext →